Biotech RadarJobs updated

COMPANY

SparingVision

sparingvision.com ↗

Clinical Phase 2

Keywords: gene therapy ophthalmology retinal diseases Rod Cone Dystrophy Retinitis Pigmentosa SPVN20 (high dose) SPVN20 (medium dose) SPVN20 (low dose) SPVN06

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

  1. Trial start Not phased (device or behavioral study): Natural History Study of Advanced RCD source ↗
  2. Trial start Phase 1/Phase 2: Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy source ↗
  3. Trial start Phase 1/Phase 2: Promising ROd-cone DYstrophy Gene therapY source ↗
  4. Trial start Not phased (device or behavioral study): Prospective Natural History Study of Retinitis Pigmentosa source ↗
  5. Trial start —: Retrospective Natural History Study of Retinitis Pigmentosa source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07854899Natural History Study of Advanced RCDNot phased (device or behavioral study)RecruitingSep 11, 20262028-09 (estimated)
NCT07807111Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone DystrophyPhase 1/Phase 2RecruitingOct 8, 20252032-03 (estimated)
NCT05748873Promising ROd-cone DYstrophy Gene therapYPhase 1/Phase 2Active, not recruitingApr 12, 20232027-02 (estimated)
NCT04285398Prospective Natural History Study of Retinitis PigmentosaNot phased (device or behavioral study)Active, not recruitingFeb 12, 2020Jun 30, 2026 (estimated)
NCT03975543Retrospective Natural History Study of Retinitis PigmentosaNot listedUnknown status (ClinicalTrials.gov)Oct 1, 2018Oct 1, 2019 (actual)
Feedback